WEST Search History

Hide Items	Regiona	Clear	Cancel

DATE: Monday, June 13, 2005

Hide?	<u>Set</u> <u>Name</u>	Query	Hit Count
	DB=U	SPT; PLUR=YES; OP=AND	
	L1	pontine.clm. or (lower same brain).clm.	73
	L2	L1 and neurotoxin.clm.	0
	L3	L1 and neuro-toxin.clm.	. 0
	L4	L1 and \$toxin.clm.	1
	L5	brain.clm. same skull.clm.	93
	L6	L5 and (botulin or botox or botulinum or neurotoxin or neuro-toxin or toxin or botulism or clostridial or clostridia).clm.	0
	L7	(botulin or botox or botulinum or neurotoxin or neuro-toxin or toxin or botulism or clostridia) or clostridia).clm.	2849
	L8	L7 and skull.clm.	1
	L9	L7 and skull.clm.	1
, n	L10	(botulin or botox or botulinum or neurotoxin or neuro-toxin or toxin or botulism or btna or btx or bt-x or btn-a).clm.	2472
	L11	L10 and (cranium or brain or intrabrain or medulla or stem or pons or cerebellum or crebrum).clm.	112
	L12	L11 and (method or process).clm.	102
	L13	L12 and (clostrid\$ or botul\$)	9

END OF SEARCH HISTORY

Euro. J. Neuro 10:3369-3378; 1998.

Other Reference Publication (2):

F. Patrick et al: "Blockade by <u>botulinum</u> neurotoxin B of cathechalamine release from adrenchromaffin cells correlates with its cleavage of synaptobrevin and a homologue present on the granules." Biochem, vol. 34, No. 16, 1995, pp. 5494-5503.

Other Reference Publication (8):

Jankovic, J., et al., editors; Therapy with Botulinum Toxin; Marcel Dekker, Inc. publisher; p. 45 (1994).

Other Reference Publication (15):

Naumann, M., et al.; <u>Botulinum</u> Toxin in the Treatment of Neurological Disorders of the Autonomic Nervous System; Arch Neurol (Aug. 1999); 56;914-916.

Other Reference Publication (16):

Ragona, R.M., et al.; Management of Parotid Sialocele with <u>Botulinum</u> Toxin; Laryngoscope; (Aug. 1999); 109: 1344-1346.

Other Reference Publication (17):

Sanchez-Prieto, J., et al.; <u>Botulinum</u> Toxin A Blocks Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes; Eur. J. Biochem. (1987); 165:675-681.

Other Reference Publication (22):

Williamson, L.C., et al.; <u>Clostridial</u> Neurotoxins and Substrate Proteolysis in Intact Neurons; The Journal of Biological Chemistry (Mar. 29, 1996); vol. 271, No. 13; pp. 7694-7699.

CLAIMS:

- 1. A <u>method</u> for treating a hyperplasic adrenal <u>medulla</u>, the <u>method</u> comprising the step of administering to the patient an effective amount of a <u>botulinum toxin</u> thereby treating a hyperplasic adrenal <u>medulla</u>.
- 2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.
- 3. The <u>method</u> of claim 1, wherein the <u>botulinum toxin</u> is selected from the group consisting of <u>botulinum toxin</u> types A, B, C, D, E, F and G.
- 4. A <u>method</u> for treating a hyperplasic adrenal <u>medulla</u>, the <u>method</u> comprising the step of administering to a hyperplasic adrenal <u>medulla</u> of a human patient a therapeutically effective amount of <u>botulinum</u> toxin type A, thereby treating the hyperplasic adrenal <u>medulla</u>.
- 5. A <u>method</u> for treating a hypertonic adrenal <u>medulla</u>, the <u>method</u> comprising the step of administering to the patient an effective amount of a <u>botulinum toxin</u> thereby treating a hypertonic adrenal <u>medulla</u>.
- 6. The method of claim 5, wherein the botulinum toxin is botulinum toxin type A.
- 7. The <u>method</u> of claim 5, wherein the <u>botulinum toxin</u> is selected from the group consisting of <u>botulinum toxin</u> types A, B, C, D, E, F and G.
- 8. A <u>method</u> for treating a hypertonic adrenal <u>medulla</u>, the <u>method</u> comprising the step of administering to a hypertonic adrenal <u>medulla</u> of a human patient a therapeutically effective amount of <u>botulinum</u> toxin type A, thereby treating the hypertonic adrenal <u>medulla</u>.

- <u>6881718</u>. 17 Apr 02; 19 Apr 05. Disulfide conjugated cell toxins and methods of making and using them. FitzGerald; David J., et al. 514/2; 514/14 514/15 530/300 530/344. C07K00136 C07K00200 A61K03800.
- 2. <u>6858580</u>. 04 Jun 01; 22 Feb 05. Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same. Ekwuribe; Nnochiri N., et al. 514/2; 424/193.1 514/12 514/21 530/345 530/410 568/613 568/618 568/622. A61K03802 A61K03817 C07K001113 C07K00200.
- 3. <u>6846484</u>. 28 Dec 01; 25 Jan 05. DTAT fusion toxin. Vallera; Daniel A., et al. 424/94.63; 424/238.1 514/12 514/802 530/380. A61K038/49 A61K039/05 A61K038/00 A61K035/14.
- 4. <u>6841515</u>. 22 Jan 02; 11 Jan 05. Production and use of biosolid granules. Burnham; Jeffrey C... 504/102; 424/475 435/262.5 504/117 504/359 504/367 514/963 514/964 588/18 588/261 588/901 71/64.02 71/64.11. A01N025/26 C05G005/00 A62D003/00.
- 5. <u>6620415</u>. 11 Jul 01; 16 Sep 03. Parkinson's disease treatment. Donovan; Stephen. 424/239.1; 424/197.11 424/234.1 424/236.1 424/408 514/2 514/937 514/963. A61K039/08 A61K039/385 A01N037/18.
- 6. <u>6350455</u>. 02 Aug 00; 26 Feb 02. Method for treating a catecholamine secretion. Donovan; Stephen. 424/239.1; 424/184.1 424/234.1 424/236.1 424/247.1 514/2 530/350. A61K039/00 A61K039/38 A61K038/02 A61K039/08 A01N037/18.
- 7. <u>5874415</u>. 06 Jun 95; 23 Feb 99. Enhancer sequence for modulating expression in epithelial cells. Kufe; Donald, et al. 514/44; 514/2 536/24.1 536/24.5. A01N043/04 A61K038/16 C07H021/04.
- 8. <u>5714468</u>. 19 Jan 96; 03 Feb 98. Method for reduction of migraine headache pain. Binder; William J. 514/14; 514/2. A61K038/10 A61K038/04.
- 9. <u>4246343</u>. 02 May 79; 20 Jan 81. Microbial detection and enumeration method and apparatus. Wilkins; Judd R., et al. 205/777.5; 204/403.01 435/287.1 435/32 435/34 435/38 435/39 435/817. C12Q001/18.

Generate Collection Print

Terms	Documents
L12 and (clostrid\$ or botul\$)	9

Prev Page Next Page Go to Doc#